Table 2 Comorbidities and pathologic serologic parameters in 259 patients with PG
Patients (absolute) | Patients (relative in%) | |
|---|---|---|
Gastrointestinal diseases | 66 | 22.5 (overall) |
Chronic active hepatitis | 11 | 16.7 |
Ulcerative colitis | 17 | 25.8 |
Crohn’s disease | 7 | 10.6 |
Diverticulosis | 9 | 13.6 |
Gastric disorders | 13 | 19.7 |
Gastric/duodenal ulcer | 4 | 6.0 |
Gastrointestinal polyps | 2 | 3.0 |
Steatohepatitis | 1 | 1.5 |
Others | 2 | 3.0 |
Arthropathy | 48 | 18.5 (overall) |
Rheumatoid arthritis | 24 | 50.0 |
a) seropositive | 21 | 43.8 |
b) seronegative | 3 | 6.3 |
Arthrosis | 17 | 25.8 |
Ankylosing spondylitis | 2 | 4.1 |
Psoriasis arthropathy | 3 | 6.3 |
Osteoporosis | 2 | 4.1 |
Haematological diseases | 10 | 3.9 (overall) |
Leukemia | 3 | 30.0 |
a) AML | 1 | 10.0 |
b) CML | 2 | 20.0 |
Lymphoma (T-cell) | 2 | 20.0 |
Multiple myeloma | 2 | 20.0 |
Macroglobulinemia | 3 | 30.0 |
Neoplasia | 22 | 8.5 (overall) |
Breast cancer | 6 | 27.3 |
Lung cancer | 3 | 13.6 |
Prostate cancer | 3 | 13.6 |
Malignant melanoma | 3 | 13.6 |
Hepatocellular carcinoma | 2 | 9.1 |
Ovarian cancer | 2 | 9.1 |
Colorectal cancer | 1 | 4.5 |
Laryngeal cancer | 1 | 4.5 |
Glioblastoma | 1 | 4.5 |
Endocrine disorders | 95 | 36.7 (overall) |
Diabetes mellitus | 66 | 69.5 |
a) type II | 60 | 63.2 |
b) type I | 6 | 6.3 |
Thyroid disease | 29 | 30.5 |
Hyperthyroidism | 9 | 9.5 |
Hypothyroidism | 18 | 19.0 |
Hashimoto’s thyroiditis | 2 | 2.1 |
Serological parameters | 181 | 69.9 (overall) |
Anemia | 118 | 65.2 |
Microcytic anaemia | 28 | 15.5 |
Auto-antibodies | 45 | 24.9 |
Anti-nuclear antibodies | 30 | 16.6 |
C-reactive protein | 181 | 100 |
Leukocytosis | 117 | 64.6 |
Elevated creatinine | 52 | 28.7 |
Renal failure | 11 | 6.1 |